Download this Article to Learn More
Around the world, sponsors and CROs are feeling the squeeze. Global trial volumes are getting to record highs, yet timelines are lengthening and budgets tightening. Regulatory complexity continues to slow start-up, recruitment hurdles persist, and data quality expectations have never been higher. Add in geopolitical uncertainty and rising operational costs, and it’s clear that the traditional model is under strain.
For companies racing to deliver new therapies, these pressures don’t just threaten efficiency – they threaten competitiveness. Every delay erodes first-mover advantage, investor confidence, and ultimately, patient access to breakthrough treatments.
That’s why forward-thinking sponsors are re-examining where and how they run studies. They’re searching for new strategies and trial environments that can deliver the holy grail of modern research: speed, scalability, and reliability – without compromise on data integrity or patient care.
For those engaged in this process, there is a location that’s quietly redefining what’s possible. Its streamlined regulatory systems, agile infrastructure, and highly engaged patient population – with around 72% willing to participate in clinical trials – are enabling sponsors to achieve what many assume only traditionally used markets can.
Those who have already discovered this advantage are setting a new global benchmark. Those who haven’t may be overlooking the smartest move they could make.
Offered Free by: Optimal
See All Resources from: Optimal
